Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
D065100:CCR5 Receptor Antagonists; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000627:therapeutic use*; D004311:Double-Blind Method; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D000077592:Maraviroc; D010919:Placebos; D014230:Triazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D010919:Placebos; D014230:Triazoles; D000077592:Maraviroc